Omeros Corporation (OMER)
Chart Events
Performance Outlook
| Previous Close | 3.6900 |
| Open | 3.6200 |
| Bid | 3.7900 x 800 |
| Ask | 3.8200 x 1200 |
| Day's Range | 3.5100 - 3.8400 |
| 52 Week Range | 1.7400 - 7.7500 |
| Volume | |
| Avg. Volume | 956,841 |
| Market Cap | 240.634M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.0400 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for OMER
Related Research
- Omeros CorporationCYTK: Lowering target price to $36.00CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $36.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.RatingFair ValueEconomic Moat2 days agoArgus Research
- Insider Monkey
Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript March 13, 2023 Operator: Good afternoon. And welcome to today’s earnings call from Omeros Corporation. At this time, all participants are in a listen-only mode. After the company’s remarks, we will conduct a question-and-answer session. Please be advised that this call is being recorded at the company’s […]
- Business Wire
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
SEATTLE, March 13, 2023--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2022, wh
